Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun;26(6):429-438.
doi: 10.1007/s11916-022-01044-8. Epub 2022 Apr 6.

Small Fiber Neuropathy

N Strand  1 , C Wie  2 , J Peck  3 , M Maita  2 , N Singh  4 , J Dumbroff  5 , V Tieppo Francio  6 , M Murphy  6 , K Chang  7 , D M Dickerson  8   9 , J Maloney  2
Affiliations
Review

Small Fiber Neuropathy

N Strand et al. Curr Pain Headache Rep. 2022 Jun.

Erratum in

  • Correction to: Small Fiber Neuropathy.
    Strand N, Wie C, Peck J, Maita M, Singh N, Dumbroff J, Tieppo Francio V, Murphy M, Chang K, Dickerson DM, Maloney J. Strand N, et al. Curr Pain Headache Rep. 2022 Jun;26(6):439. doi: 10.1007/s11916-022-01050-w. Curr Pain Headache Rep. 2022. PMID: 35460493 No abstract available.

Abstract

Purpose of review: This narrative review aims to summarize advances in the field of small fiber neuropathy made over the last decade, with emphasis on novel research highlighting the distinctive features of SFN.

Recent findings: While the management of SFNs is ideally aimed at treating the underlying cause, most patients will require pain control via multiple, concurrent therapies. Herein, we highlight the most up-to-date information for diagnosis, medication management, interventional management, and novel therapies on the horizon. Despite the prevalence of small fiber neuropathies, there is no clear consensus on guidelines specific for the treatment of SFN. Despite the lack of specific guidelines for SFN treatment, the most recent general neuropathic pain guidelines are based on Cochrane studies and randomized controlled trials (RCTs) which have individually examined therapies used for the more commonly studied SFNs, such as painful diabetic neuropathy and HIV neuropathy. The recommendations from current guidelines are based on variables such as number needed to treat (NNT), safety, ease of use, and effect on quality of life.

Keywords: Chronic pain; Neuropathic pain; Neuropathy; Pain; Pain management; Pain medicine.

PubMed Disclaimer

References

Papers of particular interest, published recently, have been highlighted as: • Of importance
    1. Tavee J, Zhou L. Small fiber neuropathy: a burning problem. Cleve Clin J Med. 2009;76(5):297–305. https://doi.org/10.3949/ccjm.76a.08070 . - DOI - PubMed
    1. Kelley MA, Hackshaw KV. Intraepidermal nerve fiber density as measured by skin punch biopsy as a marker for small fiber neuropathy: application in patients with fibromyalgia. Diagnostics (Basel). 2021;11(3). https://doi.org/10.3390/diagnostics11030536 .
    1. Egenolf N, Zu Altenschildesche CM, Kress L, Eggermann K, Namer B, Gross F, et al. Diagnosing small fiber neuropathy in clinical practice: a deep phenotyping study. Ther Adv Neurol Disord. 2021;14:17562864211004318. https://doi.org/10.1177/17562864211004318 . - DOI - PubMed - PMC
    1. Li C, Wang W, Ni W, Jin Y, Guo S, Jin J, et al. Better islet function and cardiovascular autonomic function in Chinese type 2 diabetic patients with pure small fiber neuropathy than with mixed neuropathy. Diabetes Ther. 2021;12(9):2423–36. https://doi.org/10.1007/s13300-021-01111-0 . - DOI - PubMed - PMC
    1. Levine TD. Small fiber neuropathy: disease classification beyond pain and burning. J Cent Nerv Syst Dis. 2018;10:1179573518771703. https://doi.org/10.1177/1179573518771703 . - DOI - PubMed - PMC

MeSH terms

LinkOut - more resources